Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lenalidomide + zinc diethyldithiocarbamate
- Development stage
- Preclinical
- Lead developer
- The Royal Wolverhampton NHS Trust
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Lenalidomide + Zn-DDC is an investigational combination therapy consisting of the immunomodulatory drug lenalidomide and the zinc-chelating compound zinc diethyldithiocarbamate (Zn-DDC). This combination is being evaluated for its potential to target the Hypoxia-NFκB-Cancer Stem Cell (CSC) pathway in haematological malignancies, specifically multiple myeloma. Lenalidomide acts by binding to the cereblon E3 ubiquitin ligase complex, leading to the degradation of transcription factors Ikaros (IKZF1) and Aiolos (IKZF3), while Zn-DDC (also known as Imuthiol) has demonstrated toxicity toward cancer stem cells. The combination is currently being studied in translational bench studies using patient bone marrow samples to improve treatment outcomes in relapsed or refractory multiple myeloma.
- Brand names
- Imuthiol
- Other names
- lanalidomide + Zn-DDClenalidomide + Zn-DDClenalidomide + zinc diethyldithiocarbamateImuthiol + Revlimid
02
Targets
CRBN (Cereblon)IKZF1 (Ikaros family zinc finger protein 1)IKZF3 (Zinc finger protein Aiolos)NF-κB
Beyond the preview
Go deeper on lenalidomide + zinc diethyldithiocarbamate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lenalidomide + zinc diethyldithiocarbamate.